We are committed to developing next-generation therapeutics for central nervous system disorders. Rexahn has recently concluded a Phase IIa clinical trial for major depressive disorder (MDD) with Serdaxin™, and it is also being tested for the treatment of Parkinson’s disease (PD).
Unlike the current standard treatment that treat symptomatic conditions, Serdaxin is a disease modifying drug that protects neurons from damage that can lead to dysfunction and eventual neuronal death. That is why we believe Serdaxin has the potential to become a much needed disease-modifying intervention for PD.
Zoraxel™ is another disease modifying drug that promises to alter how sexual dysfuntion is treated. For example, unlike other erectile dysfunction (ED) therapeutics that treat the condition by increasing peripheral blood flow, Zoraxel directly modulates the brain areas that control sexual activity. With its high safety profile and minimal side effects, Zoraxel has the potential to be a market leading drug and open the doors to a better understanding of sexual dysfunction.